[HTML][HTML] Sustained proliferation in cancer: Mechanisms and novel therapeutic targets
MA Feitelson, A Arzumanyan, RJ Kulathinal… - Seminars in cancer …, 2015 - Elsevier
Proliferation is an important part of cancer development and progression. This is manifest by
altered expression and/or activity of cell cycle related proteins. Constitutive activation of …
altered expression and/or activity of cell cycle related proteins. Constitutive activation of …
Ribosomal protein S6: a potential therapeutic target against cancer?
Ribosomal protein S6 (RPS6) is a component of the 40S small ribosomal subunit and
participates in the control of mRNA translation. Additionally, phospho (p)-RPS6 has been …
participates in the control of mRNA translation. Additionally, phospho (p)-RPS6 has been …
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties
C Hegedűs, C Özvegy‐Laczka, A Apati… - British journal of …, 2009 - Wiley Online Library
Background and purpose: ABC multidrug transporters (MDR‐ABC proteins) cause multiple
drug resistance in cancer and may be involved in the decreased anti‐cancer efficiency and …
drug resistance in cancer and may be involved in the decreased anti‐cancer efficiency and …
Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells
S Wu, L Fu - Molecular cancer, 2018 - Springer
Multidrug resistance (MDR) triggered by ATP binding cassette (ABC) transporter such as
ABCB1, ABCC1, ABCG2 limited successful cancer chemotherapy. Unfortunately, no …
ABCB1, ABCC1, ABCG2 limited successful cancer chemotherapy. Unfortunately, no …
Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS
S Bouchet, E Chauzit, D Ducint, N Castaing… - Clinica Chimica …, 2011 - Elsevier
BACKGROUND: Tyrosine Kinase Inhibitors (TKIs) are a class of targeted drugs for the
treatment of malignant pathologies. The metabolic profile of these drugs can result in great …
treatment of malignant pathologies. The metabolic profile of these drugs can result in great …
Nilotinib: a novel, selective tyrosine kinase inhibitor
JY Blay, M von Mehren - Seminars in oncology, 2011 - Elsevier
The development of tyrosine kinase inhibitors (TKIs) for the treatment of chronic
myelogenous leukemia (CML) was based on the discovery that CML stem and progenitor …
myelogenous leukemia (CML) was based on the discovery that CML stem and progenitor …
Thyroid dysfunction as an unintended side effect of anticancer drugs
F Torino, A Barnabei, R Paragliola, R Baldelli… - Thyroid, 2013 - liebertpub.com
Background: Several of the currently used anticancer drugs may variably affect thyroid
function, with impairment ranging from modified total but not free concentration of thyroid …
function, with impairment ranging from modified total but not free concentration of thyroid …
Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?
Introduction: Anticancer tyrosine kinase inhibitors (TKIs) are small molecule hydrophobic
compounds designed to arrest aberrant signaling pathways in malignant cells. Multidrug …
compounds designed to arrest aberrant signaling pathways in malignant cells. Multidrug …
Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitors
Abstract BACKGROUND. BCR‐ABL kinase domain (KD) mutations are detected in
approximately 45% of patients with imatinib‐resistant chronic myeloid leukemia. Patterns of …
approximately 45% of patients with imatinib‐resistant chronic myeloid leukemia. Patterns of …
Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling
R Tripathi, Z Liu, A Jain, A Lyon, C Meeks… - Nature …, 2020 - nature.com
Metastatic melanoma remains an incurable disease for many patients due to the limited
success of targeted and immunotherapies. BRAF and MEK inhibitors reduce metastatic …
success of targeted and immunotherapies. BRAF and MEK inhibitors reduce metastatic …